GlassScriptPhysician profile
Muhammad N Khan
NPI 1659347748
$2,514.87
in general payments reported to CMS, 2019-2025
12 companies · $20.07 in 2025
The $20.07 reported for 2025 was less than what a typical Vascular & Interventional Radiology provider received nationally (typical 2025 total: $537).
See the full distribution for Vascular & Interventional Radiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $838 · 2020: $18.93 · 2021: $138 · 2022: $16.91 · 2023: $1,051 · 2024: $431 · 2025: $20.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $945 · Food and Beverage: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $945.37 |
| Food and Beverage | $557.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $557.24 | 2019 | |
| Mozarc Medical US LLC | $548.60 | 2023 | Argyle, Chameleon |
| Medtronic, INC. | $519.68 | 2022-2023 | Argyle, Pipeline, Reacttm |
| Nevro Corp. | $413.39 | 2024 | Senza |
| Angiodynamics, INC. | $285.93 | 2019-2020 | |
| Terumo Medical Corporation | $43.83 | 2021 | |
| Paratek Pharmaceuticals, INC. | $42.89 | 2021 | |
| Penumbra, INC. | $30.00 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.36 | 2021 | |
| Tanabe Pharma America, INC. | $20.07 | 2025 | Radicava |
| Sumitomo Pharma America, INC. | $17.88 | 2024 | Gemtesa |
| Cook Medical LLC | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.